

Priority Health Medicare Prior Authorization Criteria (Part D)

Synribo®

Products affected

- Synribo®

Details

Covered uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion criteria	N/A
Required medical information	N/A
Age restrictions	N/A
Prescriber restrictions	N/A
Coverage duration	Authorized for one year.
Other criteria	For diagnosis of chronic myeloid leukemia, patient must have a trial with one of Gleevec (imatinib mesylate), Sprycel or Tasigna.